Bear,
if you look at the corporate presentation dated March 2019, it says in a bullet point on page 3:
*Attractive safety profile, with over 1,900 patients dosed and eight successful DSMB readouts in Phase 3.
AAttractive safety profile,
with over 1,900 patients dosed
and eight successful DSMB readouts in Phase 3